Icon

BELLUS Health Inc. Stock Analysis and Price Target COMMON STOCK | | LSE

stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

CAD 8.60

0.00 (0.00)%

N/A

2.80K

N/A

N/A

Icon

0A4U:LSE

BELLUS Health Inc. (CAD)
COMMON STOCK | LSE
CAD 8.60
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

N/A

N/A

CAD 8.60

BELLUS Health Inc. Stock Forecast

N/A

Based on the BELLUS Health Inc. stock forecast from 0 analysts, the average analyst target price for BELLUS Health Inc. is not available over the next 12 months. BELLUS Health Inc.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of BELLUS Health Inc. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, BELLUS Health Inc.’s stock price was CAD 8.60. BELLUS Health Inc.’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for BELLUS Health Inc.
No recent average analyst rating found for BELLUS Health Inc.

Company Overview BELLUS Health Inc.

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II...Read More

275 Armand-Frappier Boulevard, Laval, QC, Canada, H7V 4A7

32

December

CAD

UK

Adjusted Closing Price for BELLUS Health Inc. (0A4U:LSE)

Loading...

Unadjusted Closing Price for BELLUS Health Inc. (0A4U:LSE)

Loading...

Share Trading Volume for BELLUS Health Inc. Shares

Loading...

Compare Performance of BELLUS Health Inc. Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for 0A4U:LSE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BELLUS Health Inc. (Sector: )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
0R2F:LSE
Wells Fargo & Company -1.30 (-3.23%) CAD9,223,372,036.85B N/A N/A

ETFs Containing 0A4U

Symbol Name 0A4U's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About BELLUS Health Inc. (0A4U:LSE) Stock

Stock Target Advisor's fundamental analysis for BELLUS Health Inc.'s stock is Neutral.

Unfortunately we do not have enough data on 0A4U:LSE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on 0A4U:LSE's stock to indicate what its average analyst target is.

Unfortunately we do not have enough data on 0A4U:LSE's stock to indicate if its overvalued.

The last closing price of 0A4U:LSE's stock was CAD 8.60.

Unfortunately we do not currently have any market capitalization data for 0A4U:LSE's stock.

Unfortunately we do not have enough analyst data on 0A4U:LSE's stock to indicate whether its price will go up or not.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...